by Barry101 | Mar 22, 2024 | Press Release
OCALA, Fla., March 22, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s website. For the CEO Corner segment, Thomas Equels,...
by Barry101 | Mar 20, 2024 | Press Release
OCALA, Fla., March 20, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s website. For the CEO Corner segment, Thomas Equels,...
by Barry101 | Mar 15, 2024 | Press Release
Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Wednesday, March 20th at 12:00 PM ETOCALA, Fla., March 15, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that it...
by Barry101 | Mar 7, 2024 | Press Release
CEO Corner segments to provide added perspective to press releases, corporate developments and pipeline progress Provides interested parties the ability to ask questions and submit topics for future videos Access the AIM CEO Corner Here! OCALA, Fla., March 07, 2024...
by Barry101 | Feb 29, 2024 | Press Release
Company continues progress across Ampligen® clinical development programs Growing body of promising data demonstrates Ampligen’s potential to address multiple high-value indications OCALA, Fla., Feb. 29, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM)...
by Barry101 | Feb 14, 2024 | Press Release
Phase 1b portion of the study expected to be completed within six monthsOCALA, Fla., Feb. 14, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the first subject has been dosed at Erasmus Medical...
